

Accepted Manuscript

Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R

Kai Shi, Yan Fang, Shan Gao, Dongjuan Yang, Hongshu Bi, Jianxiu Xue, Anqi Lu, Yuai Li, Liyuan Ke, Xiaojie Lin, Xuechao Jin, Min Li



PII: S0168-3659(18)30207-4
DOI: doi:[10.1016/j.jconrel.2018.04.023](https://doi.org/10.1016/j.jconrel.2018.04.023)
Reference: COREL 9250
To appear in: *Journal of Controlled Release*
Received date: 18 November 2017
Revised date: 7 April 2018
Accepted date: 11 April 2018

Please cite this article as: Kai Shi, Yan Fang, Shan Gao, Dongjuan Yang, Hongshu Bi, Jianxiu Xue, Anqi Lu, Yuai Li, Liyuan Ke, Xiaojie Lin, Xuechao Jin, Min Li , Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2018), doi:[10.1016/j.jconrel.2018.04.023](https://doi.org/10.1016/j.jconrel.2018.04.023)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Inorganic kernel - supported asymmetric hybrid vesicles for targeting
delivery of STAT3-decoy oligonucleotides to overcome anti-HER2
therapeutic resistance of BT474R**

Kai Shi^{a,*}, Yan Fang^a, Shan Gao^a, Dongjuan Yang^a, Hongshu Bi^b, Jianxiu Xue^a, Anqi Lu^a,

Yuai Li^a, Liyuan Ke^c, Xiaojie Lin^a, Xuechao Jin^a, Min Li^a

^aDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University,
Shenyang, Liaoning 117004, P. R. China

^bLiaoning Yaolian Pharmaceutical Co., Ltd., Benxi, Liaoning 117004, P. R. China

^cLiaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, P. R. China

***Address correspondence to:** Dr. Kai Shi, Department of Pharmaceutics, School of
Pharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 117004, China. Tel:
+86-24-43520557. Email address: shikai@syphu.edu.cn.

Download English Version:

<https://daneshyari.com/en/article/7859695>

Download Persian Version:

<https://daneshyari.com/article/7859695>

[Daneshyari.com](https://daneshyari.com)